Albany, New York, June 29, 2017: The global companion diagnostic tests in oncology market is anticipated to display phenomenal growth due to rising adoption of new tests, and shift from blockbuster drugs to personalized drugs and targeted therapies. Rising prevalence of cancer, increasing financial burden of cancer treatment, and increasing mortalities due to cancer are some of the major reasons for increasing demand for new and advanced treatment options, cures, and drugs for the treatment of cancer. A new research report with a title “Companion Diagnostic Tests in Oncology Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025” has been recently added to the vast online repository of Market Research Reports Search Engine (MRRSE). The report on companion diagnostic tests in oncology market is an in-depth and professional analysis of the current situation as well as its future potential.
According to this research report, the global companion diagnostic tests in oncology market is likely to grow at a CAGR of 16.8% during the period of 2017 – 2025. At this pace, the market will reach a valuation of US$13.6 billion by the end of 2025 from US$3.5 billion in 2016. The market overview section of the report includes a qualitative analysis of the overall companion diagnostic tests in oncology market considering the aspects determining the market dynamics such as drivers, restraints, risks and opportunities, along with Porter’s five force analysis and market attractiveness analysis. Besides this, market opportunity analysis for biomarker, detection techniques, and type of cancer and major industry developments has also been provided in the report.
The global companion diagnostic tests in oncology market is segregated on the basis of detection technique, biomarker, cancer type, and end-user. The market size and forecast in terms of revenue (US$ Million) for each of these segments are provided for the period 2015 to 2025, taking 2016 as the base year. It also provides a CAGR for each segment during the forecast period 2017 to 2025. Geographically, the companion diagnostic tests in oncology market is segmented into five major regions namely Asia-Pacific, North America, Europe, Latin America, and the Middle East & Africa.
The report also provides a section on the competitive landscape analysis, in which the market share analysis of top players in the global companion diagnostic tests in oncology market, in terms of percentage share in 2016 are precisely discussed. Finally, the report concludes with the profiles of key players in the global Companion Diagnostic Tests in Oncology market such as QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., F. Hoffman LA Roche Ltd., bioMerieux SA, BioGenex, Siemens Healthcare GmBH, AGENDIA NV, and Thermo Fisher Scientific, Inc., among others. The major market players are assessed on key parameters such as company overview, financial strategies, financial overview, product portfolio, business strategies and recent developments.
Browse Full Global Companion Diagnostic Tests in Oncology Market Report with TOC : http://www.mrrse.com/companion-diagnostic-tests-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207